Literature DB >> 17053061

PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.

Rebecca J Chan1, Gen-Sheng Feng.   

Abstract

Elucidation of the molecular mechanisms underlying carcinogenesis has benefited tremendously from the identification and characterization of oncogenes and tumor suppressor genes. One new advance in this field is the identification of PTPN11 as the first proto-oncogene that encodes a cytoplasmic tyrosine phosphatase with 2 Src-homology 2 (SH2) domains (Shp2). This tyrosine phosphatase was previously shown to play an essential role in normal hematopoiesis. More recently, somatic missense PTPN11 gain-of-function mutations have been detected in leukemias and rarely in solid tumors, and have been found to induce aberrant hyperactivation of the Ras-Erk pathway. This progress represents another milestone in the leukemia/cancer research field and provides a fresh view on the molecular mechanisms underlying cell transformation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17053061      PMCID: PMC1785139          DOI: 10.1182/blood-2006-07-028829

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  81 in total

1.  Activated mutants of SHP-2 preferentially induce elongation of Xenopus animal caps.

Authors:  A M O'Reilly; S Pluskey; S E Shoelson; B G Neel
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 2.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 3.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

4.  Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development.

Authors:  C K Qu; S Nguyen; J Chen; G S Feng
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

5.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.

Authors:  Marco Tartaglia; Kamini Kalidas; Adam Shaw; Xiaoling Song; Dan L Musat; Ineke van der Burgt; Han G Brunner; Débora R Bertola; Andrew Crosby; Andra Ion; Raju S Kucherlapati; Steve Jeffery; Michael A Patton; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2002-05-01       Impact factor: 11.025

6.  Nf1 and Gmcsf interact in myeloid leukemogenesis.

Authors:  R A Birnbaum; A O'Marcaigh; Z Wardak; Y Y Zhang; G Dranoff; T Jacks; D W Clapp; K M Shannon
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

7.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia.

Authors:  Marco Tartaglia; Charlotte M Niemeyer; Alessandra Fragale; Xiaoling Song; Jochen Buechner; Andreas Jung; Karel Hählen; Henrik Hasle; Jonathan D Licht; Bruce D Gelb
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

8.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

Authors:  M Tartaglia; E L Mehler; R Goldberg; G Zampino; H G Brunner; H Kremer; I van der Burgt; A H Crosby; A Ion; S Jeffery; K Kalidas; M A Patton; R S Kucherlapati; B D Gelb
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

9.  Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers.

Authors:  Claudia A L Ruivenkamp; Tom van Wezel; Carlo Zanon; Alphons P M Stassen; Cestmir Vlcek; Tamás Csikós; Anita M Klous; Nikos Tripodis; Anastassis Perrakis; Lucie Boerrigter; Peter C Groot; Jan Lindeman; Wolter J Mooi; Gerrit A Meijjer; Gert Scholten; Hans Dauwerse; Vaclav Paces; Nico van Zandwijk; Gert Jan B van Ommen; Peter Demant
Journal:  Nat Genet       Date:  2002-06-24       Impact factor: 38.330

10.  Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling.

Authors:  Wen-Mei Yu; Teresa S Hawley; Robert G Hawley; Cheng-Kui Qu
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

View more
  138 in total

1.  Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2.

Authors:  Hla Win-Piazza; Valentina E Schneeberger; Liwei Chen; Daniele Pernazza; Harshani R Lawrence; Said M Sebti; Nicholas J Lawrence; Jie Wu
Journal:  Cancer Lett       Date:  2012-02-01       Impact factor: 8.679

2.  Somatic thrombopoietin (THPO) gene mutations in childhood myeloid leukemias.

Authors:  Maite E Houwing; Eva A Koopman-Coenen; Rogier Kersseboom; Saskia Gooskens; Inge M Appel; Susan T C J M Arentsen-Peters; Andrica C H de Vries; Dirk Reinhardt; Jan Stary; André Baruchel; Valerie de Haas; Marjolein Blink; Rob H Lopes Cardozo; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Int J Hematol       Date:  2015-03-03       Impact factor: 2.490

3.  Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).

Authors:  Xian Zhang; Yantao He; Sijiu Liu; Zhihong Yu; Zhong-Xing Jiang; Zhenyun Yang; Yuanshu Dong; Sarah C Nabinger; Li Wu; Andrea M Gunawan; Lina Wang; Rebecca J Chan; Zhong-Yin Zhang
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

4.  Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.

Authors:  Youzhou Sang; Yanli Hou; Rongrong Cheng; Liang Zheng; Angel A Alvarez; Bo Hu; Shi-Yuan Cheng; Weiwei Zhang; Yanxin Li; Haizhong Feng
Journal:  Neuro Oncol       Date:  2019-11-04       Impact factor: 12.300

Review 5.  Protein tyrosine phosphatases in the JAK/STAT pathway.

Authors:  Dan Xu; Cheng-Kui Qu
Journal:  Front Biosci       Date:  2008-05-01

6.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer.

Authors:  Jing Jiang; Mei-Shan Jin; Fei Kong; Yin-Ping Wang; Zhi-Fang Jia; Dong-Hui Cao; Hong-Xi Ma; Jian Suo; Xue-Yuan Cao
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

8.  S-nitrosylated SHP-2 contributes to NMDA receptor-mediated excitotoxicity in acute ischemic stroke.

Authors:  Zhong-Qing Shi; Carmen R Sunico; Scott R McKercher; Jiankun Cui; Gen-Sheng Feng; Tomohiro Nakamura; Stuart A Lipton
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

9.  Shp2-dependent ERK signaling is essential for induction of Bergmann glia and foliation of the cerebellum.

Authors:  Kairong Li; Alan W Leung; Qiuxia Guo; Wentian Yang; James Y H Li
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

10.  PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.

Authors:  Kristen S Hill; Evan R Roberts; Xue Wang; Ellen Marin; Taeeun D Park; Sorany Son; Yuan Ren; Bin Fang; Sean Yoder; Sungjune Kim; Lixin Wan; Amod A Sarnaik; John M Koomen; Jane L Messina; Jamie K Teer; Youngchul Kim; Jie Wu; Charles E Chalfant; Minjung Kim
Journal:  Mol Cancer Res       Date:  2018-10-24       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.